Loratadine
Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis
Maritime NeurologySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RANITIDINE Genzyme, a Sanofi Company | Phase 3 | B |
Same molecule, other indications
Loratadine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →